Attovia Therapeutics, Inc.
ATTO
$19.56
$0.381.98%
NASDAQ
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Net Income | -23.13% | ||||
| Total Depreciation and Amortization | 69.23% | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | 67.84% | ||||
| Change in Net Operating Assets | -2,032.14% | ||||
| Cash from Operations | -28.38% | ||||
| Capital Expenditure | 83.93% | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | 182.81% | ||||
| Cash from Investing | 176.76% | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | -75.56% | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | -262.90% | ||||
| Cash from Financing | -100.87% | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | -96.85% | ||||